Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Invest. 2012 Sep;122(9):3048-51. doi: 10.1172/JCI64412. Epub 2012 Aug 13.

FAM83A and FAM83B: candidate oncogenes and TKI resistance mediators.

Author information

  • 1Division of Hematology/Oncology, Virginia Commonwealth University Health Science Center, Richmond, Virginia 23229, USA. stgrant@vcu.edu

Abstract

The growth and survival of tumor cells can depend upon the expression of a single oncogene, and therapeutically targeting this oncogene addiction has already proven to be an effective approach in fighting cancer. However, it is also clear that cancer cells can adapt and become resistant to therapy through compensatory activation of downstream pathways that relieve the cell of its addicted phenotype. In this issue of the JCI, two groups--Lee et al. and Cipriano et al.--identify two related candidate oncogenes that might both contribute to therapeutic resistance to tyrosine kinase inhibitors (TKIs). If validated, this information could help to identify new targets for therapeutic interventions in breast cancer and possibly other cancers and may also assist in the development of strategies designed to overcome resistance to currently available TKIs.

Publication Types

Publication Types

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Journal of Clinical Investigation Icon for PubMed Central
    Loading ...
    Write to the Help Desk